Recent studies and meta-analyses have shown higher prevalences of neonatal complications, mainly macrosomia and neonatal hypoglycemia, in users of glyburide [25–32], and higher prevalences of preterm birth and preeclampsia in users of metformin [33–36], compared with users of insulin. The gene discussed is INS; the disease is preeclampsia.